Advertisement

Cancer Causes & Control

, Volume 30, Issue 12, pp 1283–1291 | Cite as

Racial differences in brain cancer characteristics and survival: an analysis of SEER data

  • Julie A. Bytnar
  • Jie Lin
  • Craig D. Shriver
  • Kangmin ZhuEmail author
Original Paper
  • 54 Downloads

Abstract

Purpose

Racial disparity with shorter survival for Blacks than Whites is well known for many cancers. However, for brain cancer, some national cancer registry studies have shown better survival among Blacks compared to Whites. This study aimed to systematically investigate whether Blacks and Whites differ in survival and also in tumor characteristics and treatment for neuroepithelial brain tumors.

Methods

The National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) database was used to identify non-Hispanic White and Black patients diagnosed with malignant, histologically confirmed neuroepithelial brain cancer from 2004 through 2015. Racial differences in brain cancer survival were compared using Kaplan–Meier curve and Cox proportional hazard models. The associations of race with tumor and treatment characteristics (location, size, grade, surgical type) were examined using multinomial logistic regression.

Results

After adjusting for demographic, tumor, and treatment factors, there were no significant differences in survival for non-Hispanic Blacks compared to non-Hispanic Whites [hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.99–1.10]. Non-Hispanic Blacks had higher odds of being diagnosed with tumors of unknown grade [odds ratio (OR) 1.16, 95% CI 1.05–1.29], unknown size (OR 1.14, 95% CI 1.01–1.29), infratentorial (OR 1.12, 95% CI 1.01–1.24) or overlapping area (OR 1.39, 95% CI 1.14–1.70), and lower odds of having a total surgical resection (OR 0.83, 95% CI 0.74–0.93).

Conclusion

Non-Hispanic Blacks do not exhibit longer brain cancer-specific survival than non-Hispanic Whites. They were more likely to have tumors of unknown size or grade and less likely to receive total surgical resection, which may result from racial differences in access to and use of healthcare.

Keywords

Brain cancer Disparity Survival SEER 

Notes

Funding

This project was supported by the Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center under the auspices of the Henry M. Jackson Foundation for the Advancement of Military Medicine.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A (2016) Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin 66(4):290–308.  https://doi.org/10.3322/caac.21340 CrossRefPubMedGoogle Scholar
  2. 2.
    DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67(6):439–448.  https://doi.org/10.3322/caac.21412 CrossRefPubMedGoogle Scholar
  3. 3.
    Yoo W, Kim S, Huh WK, Dilley S, Coughlin SS, Partridge EE, Chung Y, Dicks V, Lee JK, Bae S (2017) Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS ONE 12(2):e0172548.  https://doi.org/10.1371/journal.pone.0172548 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lin JJ, Mhango G, Wall MM, Lurslurchachai L, Bond KT, Nelson JE, Berman AR, Salazar-Schicchi J, Powell C, Keller SM, Halm EA, Leventhal H, Wisnivesky JP (2014) Cultural factors associated with racial disparities in lung cancer care. Ann Am Thorac Soc 11(4):489–495.  https://doi.org/10.1513/AnnalsATS.201402-055OC CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Benjamins MR, Hunt BR, Raleigh SM, Hirschtick JL, Hughes MM (2016) Racial disparities in prostate cancer mortality in the 50 largest US cities. Cancer Epidemiol 44:125–131.  https://doi.org/10.1016/j.canep.2016.07.019 CrossRefPubMedGoogle Scholar
  6. 6.
    Robbins AS, Siegel RL, Jemal A (2012) Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol 30(4):401–405.  https://doi.org/10.1200/jco.2011.37.5527 CrossRefPubMedGoogle Scholar
  7. 7.
    Khawja SN, Mohammed S, Silberfein EJ, Musher BL, Fisher WE, Van Buren G II (2015) Pancreatic cancer disparities in African Americans. Pancreas 44(4):522–527.  https://doi.org/10.1097/mpa.0000000000000323 CrossRefPubMedGoogle Scholar
  8. 8.
    Jinjuvadia R, Jinjuvadia K, Liangpunsakul S (2013) Racial disparities in gastrointestinal cancers-related mortality in the U.S. population. Dig Dis Sci 58(1), 236–243. DOI: 10.1007/s10620-012-2312-3.Google Scholar
  9. 9.
    Siegel RL, Miller KD (2016) Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30.  https://doi.org/10.3322/caac.21332 CrossRefGoogle Scholar
  10. 10.
    Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 20(4):E1.  https://doi.org/10.3171/foc.2006.20.4.E1 CrossRefPubMedGoogle Scholar
  11. 11.
    Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103(9):714–736.  https://doi.org/10.1093/jnci/djr077 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer 98(3):603–609.  https://doi.org/10.1002/cncr.11534 CrossRefPubMedGoogle Scholar
  13. 13.
    Barnholtz-Sloan JS, Maldonado JL, Williams VL, Curry WT, Rodkey EA, Barker FG II, Sloan AE (2007) Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neurooncol 85(2):171–180.  https://doi.org/10.1007/s11060-007-9405-4 CrossRefPubMedGoogle Scholar
  14. 14.
    Pan IW, Ferguson SD, Lam S (2015) Patient and treatment factors associated with survival among adult glioblastoma patients: a USA population-based study from 2000–2010. J Clin Neurosci 22(10):1575–1581.  https://doi.org/10.1016/j.jocn.2015.03.032 CrossRefPubMedGoogle Scholar
  15. 15.
    Bohn A, Braley A, Rodriguez de la Vega P, Zevallos JC, Barengo NC (2018) The association between race and survival in glioblastoma patients in the US: A retrospective cohort study. PLoS ONE 13(6):e0198581.  https://doi.org/10.1371/journal.pone.0198581 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313(2):165–173.  https://doi.org/10.1001/jama.2014.17322 CrossRefPubMedGoogle Scholar
  17. 17.
    Efird JT, Landrine H, Shiue KY, O'Neal WT, Podder T, Rosenman JG, Biswas T (2014) Race, insurance type, and stage of presentation among lung cancer patients. SpringerPlus 3:710.  https://doi.org/10.1186/2193-1801-3-710 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sayegh ET, Aranda D, Kim JM, Oh T, Parsa AT, Oh MC (2014) Prognosis by tumor location in adults with intracranial ependymomas. J Clin Neurosci 21(12):2096–2101.  https://doi.org/10.1016/j.jocn.2014.05.011 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 114(2):97–109.  https://doi.org/10.1007/s00401-007-0243-4 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Butowski NA (2015) Epidemiology and diagnosis of brain tumors. Continuum (Minneapolis, Minn) 21(2 Neuro-oncology):301–313.  https://doi.org/10.1212/01.CON.0000464171.50638.fa CrossRefGoogle Scholar
  21. 21.
    Claus EB, Black PM (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 106(6):1358–1363.  https://doi.org/10.1002/cncr.21733 CrossRefPubMedGoogle Scholar
  22. 22.
    Silber JH, Rosenbaum PR, Clark AS, Giantonio BJ, Ross RN, Teng Y, Wang M, Niknam BA, Ludwig JM, Wang W, Even-Shoshan O, Fox KR (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310(4):389–397.  https://doi.org/10.1001/jama.2013.8272 CrossRefPubMedGoogle Scholar
  23. 23.
    National Cancer Institute Surveillance Epidemiology and End Result Program (2018) https://seer.cancer.gov/registries/. Accessed 29 June 2018
  24. 24.
    Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19(suppl_5):v1–v88.  https://doi.org/10.1093/neuonc/nox158
  25. 25.
    McCarthy BJ, Surawicz T, Bruner JM, Kruchko C, Davis F (2002) Consensus conference on brain tumor definition for registration. November 10, 2000. Neuro Oncol 4(2):134–145.  https://doi.org/10.1093/neuonc/4.2.134 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Chandana SR, Movva S, Arora M, Singh T (2008) Primary brain tumors in adults. Am Fam Physician 77(10):1423–1430PubMedGoogle Scholar
  27. 27.
  28. 28.
    Nizamutdinov D, Stock EM, Dandashi JA, Vasquez EA, Mao Y, Dayawansa S, Zhang J, Wu E, Fonkem E, Huang JH (2018) Prognostication of survival outcomes in patients diagnosed with glioblastoma. World Neurosurg 109:e67–e74.  https://doi.org/10.1016/j.wneu.2017.09.104 CrossRefPubMedGoogle Scholar
  29. 29.
    Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK (2017) Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djx030 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Gittleman H, Kromer C, Ostrom QT, Blanda R, Russell J, Kruchko C, Barnholtz-Sloan JS (2017) Is mortality due to primary malignant brain and other central nervous system tumors decreasing? J Neurooncol 133(2):265–275.  https://doi.org/10.1007/s11060-017-2449-1 CrossRefPubMedGoogle Scholar
  31. 31.
    Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS (2018) Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 4(9):1254–1262.  https://doi.org/10.1001/jamaoncol.2018.1789 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    McGuire CS, Sainani KL, Fisher PG (2009) Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer 52(1):65–69.  https://doi.org/10.1002/pbc.21806 CrossRefPubMedGoogle Scholar
  33. 33.
    Daniel CL, Gilreath K, Keyes D (2017) Colorectal cancer disparities beyond biology: Screening, treatment, access. Front Biosci (Landmark Ed) 22:465–478CrossRefGoogle Scholar
  34. 34.
    Press R, Carrasquillo O, Sciacca RR, Giardina EG (2008) Racial/ethnic disparities in time to follow-up after an abnormal mammogram. J Womens Health (Larchmt) 17(6):923–930.  https://doi.org/10.1089/jwh.2007.0402 CrossRefGoogle Scholar
  35. 35.
    Coughlin SS, Blumenthal DS, Seay SJ, Smith SA (2016) Toward the elimination of colorectal cancer disparities among African Americans. J Racial Ethn Health Disparities 3(4):555–564.  https://doi.org/10.1007/s40615-015-0174-z CrossRefPubMedGoogle Scholar
  36. 36.
    Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii93–101. 10.1093/annonc/mdu050Google Scholar
  37. 37.
    Kiechle JE, Abouassaly R, Gross CP, Dong S, Cherullo EE, Zhu H, Trinh QD, Sun M, Meropol NJ, Hoimes CJ, Ialacci S, Kim SP (2016) Racial disparities in partial nephrectomy persist across hospital types: results from a population-based cohort. Urology 90:69–74.  https://doi.org/10.1016/j.urology.2015.10.035 CrossRefPubMedGoogle Scholar
  38. 38.
    Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E (2008) Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998–2005). J Natl Cancer Inst 100(7):462–474.  https://doi.org/10.1093/jnci/djn057 CrossRefPubMedGoogle Scholar
  39. 39.
    Dehal A, Abbas A, Johna S (2013) Racial disparities in clinical presentation, surgical treatment and in-hospital outcomes of women with breast cancer: analysis of nationwide inpatient sample database. Breast Cancer Res Treat 139(2):561–569.  https://doi.org/10.1007/s10549-013-2567-1 CrossRefPubMedGoogle Scholar
  40. 40.
    Bristow RE, Zahurak ML, Ibeanu OA (2011) Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol 121(2):364–368.  https://doi.org/10.1016/j.ygyno.2010.12.347 CrossRefPubMedGoogle Scholar
  41. 41.
    Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE (2008) Patterns of care in elderly glioblastoma patients. Ann Neurol 64(6):628–634.  https://doi.org/10.1002/ana.21521 CrossRefPubMedGoogle Scholar
  42. 42.
    Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102(20):1584–1598.  https://doi.org/10.1093/jnci/djq366 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Utada M, Ohno Y, Shimizu S, Hori M, Soda M (2012) Comparison between overall, cause-specific, and relative survival rates based on data from a population-based cancer registry. Asian Pac J Cancer Prev 13(11):5681–5685CrossRefGoogle Scholar
  44. 44.
    Sarfati D, Blakely T, Pearce N (2010) Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol 39(2):598–610.  https://doi.org/10.1093/ije/dyp392 CrossRefPubMedGoogle Scholar
  45. 45.
    Ening G, Osterheld F, Capper D, Schmieder K, Brenke C (2015) Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. J Cancer Res Clin Oncol 141(6):1131–1137.  https://doi.org/10.1007/s00432-014-1907-9 CrossRefPubMedGoogle Scholar
  46. 46.
    Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2012) Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma. J Neurooncol 106(2):383–389.  https://doi.org/10.1007/s11060-011-0676-4 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Julie A. Bytnar
    • 1
    • 2
  • Jie Lin
    • 1
    • 2
    • 3
  • Craig D. Shriver
    • 1
    • 3
  • Kangmin Zhu
    • 1
    • 2
    • 4
    Email author
  1. 1.John P. Murtha Cancer CenterUniformed Services University of the Health Sciences and Walter Reed National Military Medical CenterBethesdaUSA
  2. 2.Henry M. Jackson Foundation for the Advancement of Military MedicineBethesdaUSA
  3. 3.Department of SurgeryUniformed Services University of the Health SciencesBethesdaUSA
  4. 4.Department of Preventive Medicine and BiostatisticsUniformed Services University of the Health SciencesBethesdaUSA

Personalised recommendations